Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Minnesota Attorney General Keith Ellison says he will announce "a major development in his litigation against the three ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

MoneywebNOW took a look at whether GLP-1 drugs present a good investment opportunity, future inflation expectations and more.

There’s a little problem, though: most of the decline in the seven comes down to one company. Apple is down 14 per cent since ...